Zhejiang publishes the list of "preferential" drugs for bidding and supplements the drugs in short supply

Source: from Zhejiang Pharmaceutical machinery purchasing center on November 20, 2014, the reporter from wisdom astak news agency learned that part of the data review results of 2014 drug centralized purchase (the first batch) in Zhejiang Province had been published, and varieties of Hengrui pharmaceutical, Kangenbei, China new pharmaceutical, Beijing new pharmaceutical, Luoxin pharmaceutical and other listed companies were shortlisted, which is expected to enjoy better quality level treatment It is understood that the review conclusions issued by Zhejiang province include 5 aspects, namely, patented compound products, traditional Chinese medicine products with "zhebaiwei" as the main component, products with additional devices, products meeting the requirements of pharmacoeconomic evaluation and products meeting the international level of generic drugs According to the insiders, Zhejiang is a big bidding Province, and these varieties may benefit from bidding in the future and grow into super large varieties in Zhejiang market In terms of compound patents, only oseltamivir phosphate capsule of Shanghai Roche pharmaceutical was recognized Among the traditional Chinese medicine products with "zhebaiwei" as the main ingredient, 40 products of 15 bidding enterprises were shortlisted, including Yuanhu Zhitong Capsule of Kangenbei, Shengmai drink of Zhengda qingqingbao, etc Nine products with additional devices from six companies, including Chenxin pharmaceutical and Luoxin pharmaceutical, are also selected It is worth mentioning that Zhejiang is the first province in China to separate the drugs with additional devices, which has aroused wide controversy in the industry In addition, among the products that meet the requirements of pharmacoeconomic evaluation, 16 product specifications of 9 bidding enterprises such as Kangenbei have passed the evaluation, while 36 product specifications of 14 bidding enterprises such as Dongrui pharmaceutical, Hengrui pharmaceutical and Jingxin pharmaceutical have reached the international level in the evaluation, and these products can add additional points in the evaluation of economic and technical bids